康辰藥業(603590.SH):5%以上股東GL減持56.01萬股 當前持股5%
格隆匯9月4日丨康辰藥業(603590.SH)公佈,公司於2020年9月4日收到GL發來的《關於北京康辰藥業股份有限公司股票減持進展的告知函》。
GL根據2020年4月28日披露的減持股份計劃,於2020年8月27日至9月4日通過集中競價交易方式減持公司股份56.01萬股,佔公司總股本的0.35%。
本次權益變動前,GL持有公司股份856萬股,佔公司總股本的5.35%;本次權益變動後,GL持有公司股份799.99萬股,佔公司總股本的5.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.